39 completed, 19 unknown, 7 recruiting, 6 terminated. 31 Phase 2, 30 Phase 3, 12 Phase 1, 4 Not applicable, 2 Phase 4.
Follow favipiravir: new trials by email Literature Review of favipiravir trials Research Report on favipiravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF Favipiravir, Ribavin, Optimised Standard of Care - Crimean-Congo Hemorrhagic Fever | Phase 2 | Recruiting | Liverpool School of Tropical Medicine | 378 | 2026-06-04 | 2026-08-07 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| Assessing Antiviral Treatments in Early Symptomatic RSV Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human | Phase 2 | Recruiting | University of Oxford | 1000 | 2024-07-25 | 2025-07-02 |
| Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers favipiravir, Placebo - Infectious Disease, Pharmacology | Phase 1 | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 39 | 2024-05-14 | 2026-02-12 |
| UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF Favipiravir, Ribavirin - CCHF | Phase 1 / Phase 2 | Unknown | Liverpool School of Tropical Medicine | 24 | 2023-07-12 | 2023-10-05 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human | Phase 2 | Recruiting | University of Oxford | 3000 | 2023-02-22 | 2026-04-14 |
| Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir - COVID-19 | Phase 4 | Completed | Mansoura University Hospital | 265 | 2022-09-02 | 2023-07-25 |
| Efficacy and Safety of JT001 (VV116) Compared With Favipiravir JT001, JT001 placebo, Favipiravir - Moderate to Severe COVID-19 | Phase 3 | Terminated | Shanghai Vinnerna Biosciences Co., Ltd. | 290 | 2022-03-14 | 2023-02-08 |
| Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19 Favipiravir, Nitazoxanide, Nitazoxanide Placebo - Covid19 | Phase 2 | Completed | Coordinación de Investigación en Salud, Mexico | 120 | 2021-10-12 | 2023-03-24 |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19 Favipiravir, Remdesivir - COVID-19 | Phase 3 | Completed | Promomed, LLC | 217 | 2021-08-11 | 2022-01-11 |
| OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA Remdesivir - Duration of Hospitalization, Clinical Manifestation of COVID-19 | Completed | Bernadette Dian Novita, MD.,PhD | 87 | 2021-08-01 | 2022-02-03 | |
| Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever Ribavirin iv, Favipiravir - Lassa Fever | Phase 2 | Completed | Bernhard Nocht Institute for Tropical Medicine | 40 | 2021-07-30 | 2023-02-08 |
| Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy - COVID-19 | Phase 2 | Terminated | Hospital General de México Dr. Eduardo Liceaga | 19 | 2021-07-13 | 2022-06-03 |
| Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection Plitidepsin, Dexamethasone, Remdesivir - COVID-19 Infection | Phase 3 | Terminated | PharmaMar | 205 | 2021-06-04 | 2025-02-21 |
| Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients Kunamin®, Favipiravir, Enoxaparin - COVID-19 Respiratory Infection, FLU | Phase 3 | Completed | RAAS Nutritionals, LLC | 71 | 2021-05-29 | 2022-06-14 |
| Investigation the Effect of Montelukast in COVID-19 Montelukast Oral Tablet, Montelukast plus Favicovir (Favipiravir), Favicovir (Standard Treatment) - COVID-19, SARS-CoV-2 | Phase 2 | Unknown | Bahçeşehir University | 380 | 2021-05-15 | 2022-04-28 |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| Favipiravir in High-risk COVID-19 Patients Favipiravir - Covid19 | Phase 3 | Completed | Penang Hospital, Malaysia | 500 | 2021-02-16 | 2021-11-24 |
| Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal Favipiravir, Placebo, Remdesivir - Covid19 | Phase 3 | Unknown | Nepal Health Research Council | 676 | 2021-01-01 | 2021-01-05 |
Showing 20 of 71. Sign in to see all of them.
COVID-19 (43) · Influenza, Human (7) · Communicable Diseases (2) · Coronavirus Infections (2) · Cough (2) · Fatigue (2) · Fever (2) · Headache (2) · Hemorrhagic Fever, Ebola (2) · Hemorrhagic Fevers, Viral (2) · Lassa Fever (2) · Nasal Obstruction (2) · Pharyngitis (2) · Common Cold (1) · Communicable Diseases, Emerging (1)
MDVI, LLC (5) · Institut National de la Santé Et de la Recherche Médicale, France (3) · University of Oxford (3) · Appili Therapeutics Inc. (2) · King Abdullah International Medical Research Center (2) · Liverpool School of Tropical Medicine (2) · Ministry of Health, Turkey (2) · Peking University First Hospital (2) · Promomed, LLC (2) · Afyonkarahisar Health Sciences University (1) · Ain Shams University (1) · Astana Medical University (1) · Atabay Kimya Sanayi Ticaret A.S. (1) · Bahçeşehir University (1) · Bangladesh Medical Research Council (BMRC) (1)
Turkey (Türkiye) (15) · United States (8) · Brazil (6) · China (6) · Mexico (6) · Russia (5) · Egypt (4) · Indonesia (4) · South Africa (4) · Australia (3) · Laos (3) · Nepal (3) · Thailand (3) · United Kingdom (3) · Bulgaria (2)
Muradiye Nacak, MD,PhD (5) · Taner Ezgi, MD (3) · Carol Epstein, MD (2) · Guiqiang Wang (2) · Ahmad Alaskar (1) · Ahmed Elshafeey, Ph.D. Pharma (1) · Allison J McGeer, MD (1) · Almena L. Free, MD (1) · April Palmer, MD (1) · Arles Perdomo, MD (1) · Barry K McLean, MD (1) · Barry N Heller, MD (1) · Brian K Allen, DO (1) · Charles M. Schwarz, MD (1)
PMID 34473343, PMID 35127447, PMID 35639525, PMID 37739792, PMID 21406435, PMID 23697469, PMID 25213733, PMID 26930627, PMID 27046271, PMID 28231247, PMID 28464462, PMID 28583578, PMID 28880856, PMID 29077848, PMID 32503657, PMID 32770240, PMID 33050947, PMID 33129363, PMID 33492523, PMID 33624010, PMID 33685502, PMID 33853806, PMID 34319552, PMID 34450619, PMID 34699618, PMID 34849615, PMID 34888401, PMID 35271729, PMID 35322077, PMID 35446944, PMID 35869526, PMID 36065065, PMID 36260627, PMID 36272432, PMID 36435798, PMID 36528039, PMID 36803992, PMID 37220480, PMID 37470445, PMID 37778363, PMID 38225598, PMID 38677300, PMID 39182994, PMID 39896880, PMID 41082886, PMID 41321979, PMID 41848748, PMID 42141199, PMID 42520824